drugset / Trial / NCT01434069

Phase I Trial of Combination of FOLFIRI and SOM 230

NCT01434069

NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open-label, phase I study of combination therapy with SOM 230 and FOLFIRI. We will utilize a sequential dose-escalation design to define the maximum tolerated dose (MTD) of SOM 230 when combined with standard doses of FOLFIRI.

Timeline

Start
2011-09
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Pasireotide Other / unclassified Intramuscular
Background Leucovorin Small molecule Intravenous
Background fluorouracil Small molecule Intravenous
Background irrinotecan Unknown Intravenous